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SUMMARY  
 Introduction : The first-choice drug therapy in the management of type 2 diabetes is 
metformin. However, most patients require a combined therapy to reach and/or maintain 
targets of glucose control. Dipeptidylpeptidase-4 (DPP-4) inhibitors, commonly referred to as 
gliptins, offer new options for combined therapy with metformin. Linagliptin is the most 
recent launched gliptin, with a unique pharmacokinetic profile characterized by negligible 
renal excretion, and is now also available as a fixed-dose combination (FDC) with metformin. 
Area covered: An extensive literature search was performed to analyze the potential 
pharmacokinetic (PK) and pharmacodynamic (PD) interactions between linagliptin and 
metformin. Linaglipin and metformin may be administered together, either separately or as 
FDC supported by bioequivalence studies. Linagliptin and metformin are not prone to PK 
drug-drug interactions. Their co-administration improves blood glucose control more potently 
than either compound separately, without hypoglycemia and without increasing metformin-
related gastrointestinal side effects.  
Expert Opinion : The combination linaglitpin plus metformin, if not contraindicated (renal 
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1. Introduction  
 The management of hyperglycemia in patients with type 2 diabetes mellitus (T2DM) 
becomes more and more complex1-3. After failure of metformin monotherapy, several 
pharmacological options may be considered3-6, among which the addition of a selective inhibitor 
of dipeptidyl peptidase-4 (DPP-4) occupies an increasing place in clinical practice7-9. Indeed, a 
progressive deterioration of the glycemic control is generally observed over years in patients 
with T2DM, which essentially results from an unavoidable decline of insulin secretion10 and 
imposes a stepwise increasing use of combined therapies2, 3. Even if metformin is unanimously 
considered as the first-line drug therapy in T2DM3, 11-13, which treatment to be added after 
metformin failure remains a quite challenging issue 14. Indeed, whatever the mode of action, 
almost all second-drug therapies offer quite similar efficacy regarding glycated hemoglobin 
(HbA1c) lowering effect4, 12. However, T2DM is often accompanied by other conditions and 
risk factors, on which the various glucose-lowering agents may exert different effects that 
may have an impact on long-term clinical outcomes and, thereby, may influence physician’s 
drug choice15, 16. Classical insulin secretagogues include sulfonylureas (still recommended 
because of their low cost)3, but these glucose-lowering agents expose to a risk of potentially 
severe hypoglycemia4, 9, 17, 18, weight gain 4, 9, 18-20 and pharmacokinetics (PK) interactions21, 
which may worsen outcomes16. In this regard, DPP-4 inhibitors, which inhibit the inactivation 
of glucagon-like peptide- 1 (GLP-1), may offer new opportunities in the management of 
T2DM8, 9, 20, 22. Indeed, GLP-1 stimulates insulin secretion and inhibits glucagon secretion in a 
glucose-dependent manner, which explains the minimal risk of hypoglycemia associated with 
such incretin-based therapies8. Furthermore, GLP-1 contributes to appetite regulation and 
thereby may avoid or at least limit weight gain despite improvement of glucose control in T2DM 
patients, in contrast to what is generally observed with other glucose-lowering therapies19, 20. 
However, the positioning of DPP-4 inhibitors in the management of T2DM, especially their 
place compared to either sulfonylureas23-25 or injectable GLP-1 receptor agonists26, 27, is still a 
matter of debate. 
 
 Several DPP-4 inhibitors are already available since many years (sitagliptin, saxagliptin, 
vildagliptin except in US, alogliptin only in Japan)8, 9, 28. Despite a similar mode of action, i.e. 
selective inhibition of DPP-4 resulting in a physiological increase in active GLP-1 levels, they 
differ by some PK properties29, 30. Most of them are also available as fixed dose combination 
(FDC) with metformin, especially vildagliptin31, 32, sitagliptin33, 34 and saxagliptin35. FDC can 
offer convenience, reduce the pill burden and simplify administration regimens for the patient, 
all conditions that may improve adherence to therapy36-38. 
 
 Linagliptin is the newest DPP-4 inhibitor and is characterized by specific PK 
properties as summarized in numerous recent reviews30, 39-43. The most clinically relevant 
specificity, relative to other already available DPP-4 inhibitors, is that linagliptin has a 
minimal renal excretion and instead a predominant biliary excretion29, 44. Thus, it may be used 
in patients with chronic kidney disease (CKD) without dose adjustment44. This contrasts with 
other DPP-4 inhibitors, for which a dose reduction is recommended according to the decrease 
of the estimated glomerular filtration rate (eGFR)45. Therefore, linagliptin may be considered 
as a valuable alternative in T2DM patients with impaired renal function in whom metformin 
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may be contraindicated46, 47. However, in T2DM patients who may receive metformin 
(because of acceptable renal function and good gastrointestinal tolerance), linagliptin may 
also be added to the biguanide to reach HbA1c targets in case of failure of monotherapy. 
Thus, linagliptin may be used in dual therapy with metformin, a well-known positioning for 
all DPP-4 inhibitors7, 23, or even in triple therapy when added to metformin plus 
sulfonylurea48, 49. A linagliptin plus metformin hydrochloride fixed-dose combination (FDC : 
Jentadueto®) has been accepted in 2012 by the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA). Even in combination, linagliptin may be used without 
dose adjustment in case of renal impairment, which contrasts with the dose reduction 
recommended for other DPP-4 inhibitors in T2DM patients with mild to moderate CKD45, as 
recently reviewed for the saxagliptin plus metformin combination50. 
 The present paper provides a PK/ pharmacodynamic (PD) evaluation of linagliptin 
plus metformin and an updated review of the randomized clinical trials and of the 
bioequivalence studies that have assessed the efficacy and tolerability/safety of this linaglitin-
metformin combination. To identify relevant studies, an extensive literature search of 
MEDLINE was performed from January 2008 to October 2012, with the two key-words 
“metformin” and “linagliptin”. No language restrictions were imposed. Reference lists of 
original studies, narrative reviews, and previous systematic reviews were also scrutinized. The 
European Public Assessment Report (EPAR) of the Committee for Medicinal Products for 
Human Use (CHMP) of the European Medicines Agency (EMA) of the FDC Juntadueto®51 
and the approval document of Juntadueto® by the Food and Drug Administration (FDA)52 
have been examined too. 
 
2. Pharmacokinetic evaluation 
 2.1. Metformin 
 Metformin hydrochloride has an absolute oral bioavailability of 40 to 60%, and 
gastrointestinal absorption is apparently complete within 6 hours of ingestion53, 54. An inverse 
relationship is observed between the dose ingested and the relative absorption with 
therapeutic doses ranging from 0.5 to 1.5 g, suggesting the involvement of an active, saturable 
absorption process. Food decreased the extent and slightly delays the absorption of 
metformin, with a 40% lower plasma peak concentration (Cmax), a 24% decrease in area under 
the plasma concentration time curve (AUC) and a 37-minute prolongation of time to peak 
plasma concentration (tmax) following administration of a dose of 850 mg metformin with a 
meal instead after an overnight fast55. However, the clinical relevance of these changes is 
unknown.  
Metformin is rapidly distributed following absorption and does not bind to plasma 
proteins. No metabolites or conjugates of metformin have been identified. Metformin 
undergoes renal excretion and has a mean plasma elimination half-life (t1/2) after oral 
administration of between 4.0 and 8.7 hours53, 54. This elimination is prolonged in patients 
with CKD and correlates with creatinine clearance56. 
 Recent studies showed that organic cation transporters (OCTs) are responsible for the 
intestinal, hepatic and renal transport of metformin57. In vitro observations showed that OCT1 
is responsible for the hepatic uptake as well as playing a role in the intestinal uptake of 
metformin58. Other in vitro findings suggested that metformin is a superior substrate for renal 
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OCT2 rather than hepatic OCT1, and renal OCT2 plays a dominant role for metformin PK59. 
Genetic polymorphisms in OCT1 and OCT2 have been found to be associated with changes in 
PK/PD responses to substrate drugs, including metformin, although the results are still 
controversial60. 
 Only limited drug-drug interactions (DDIs) have been described with metformin both 
in healthy volunteers and in T2DM patients21, 53, 61. Linagliptin showed inhibitory potency to 
OCT1 and OCT262. However, considering the low therapeutic plasma concentration of 
linagliptin, available in vitro data clearly suggest a very low risk for transporter-mediated 
DDIs on comedications, including metformin, in clinical practice62. 
 
 2.2. Linagliptin 
 The most clinically specificity of linagliptin compared with other available DPP-4 
inhibitors concerns its minimal renal excretion29, 44. We have reviewed the PK properties of 
linagliptin, as compared with those of other DPP-4 inhibitors, emphasizing its negligible renal 
excretion and its low potential of DDIs29, 63. Furthermore, the PK and PD characteristics of 
linagliptin have been extensively reviewed in two recent papers64, 65.  
In vitro studies demonstrated that linagliptin is a substrate of OCT2 and P-
glycoprotein (P-gp), suggesting that OCT2 and P-gp may play a role in the disposition of 
linagliptin in vivo62. 
2.2.1. Healthy volunteers 
A single rising-dose (2.5 up to 600 mg) study investigated the PK/PD profiles of 
linagliptin in healthy men66. Linagliptin was rapidly absorbed, with tmax values ranging from 
0.7 to 3 hours. Exposure of linagliptin increased less than proportionally from 2.5 mg to 5 mg, 
more than proportionally from 25 mg to 100 mg and approximately proportionally for doses 
from 100 mg to 600 mg. The geometric mean terminal t1/2 ranged from 128 to 184 hours. 
Renal excretion was low and almost complete after 24 hours. The fraction of dose excreted 
unchanged in urine was dose-dependent and increased from below 1% in the 5 mg group up 
to about 33% in the 600 mg group. The PK and metabolism of linagliptin were investigated 
further in healthy volunteers67. The 10- and 5-mg 14C-labeled drug was administered orally or 
intravenously, respectively. Fecal excretion was the dominant excretion pathway with 84.7% 
and 58.2% of the dose, while renal excretion accounted for 5.4% and 30.8% of the dose, after 
oral and intravenous administration, respectively. Several metabolites were identified but it 
was concluded that they only play a minor role in the overall disposition and elimination of 
the drug67. 
A single rising-dose, randomized, four-group, placebo-controlled study was performed 
in healthy men to investigate PK and PD of linagliptin after intravenous administration (0.5 
mg, 2.5 mg, 10 mg) and to determine the absolute bioavailability of the drug (comparison 
between 5 mg intravenous and 10 mg oral administration)68. Linagliptin showed nonlinear PK 
after intravenous infusion of 0.5-10 mg, with a less than dose-proportional increase in 
exposure. Renal excretion of the unchanged parent compound increased with increasing 
plasma concentrations from 2.72% in the 0.5 mg dose group to 23.0% in the 10 mg dose 
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group. Although unbound linagliptin is cleared efficiently, the concentration-dependent 
binding is responsible for the long terminal t1/2 (126-139 hours across dose groups) of 
linagliptin and its nonlinear PK, independent of the mode of administration (intravenous or 
oral). By a modelling approach avoiding the problem of a nonlinear PK, the absolute 
bioavailability of the 10 mg linagliptin tablet was estimated to be about 30%. The model 
demonstrated that the target binding to DPP-4 has a major impact on linagliptin PK and 
largely explains its nonlinear pattern69. Furthermore, results from modeling and simulation 
support a stable antidiabetic effect of linagliptin over 24 h at steady state and further indicate 
a low risk for off-target side effects70. These PK characteristics obtained in Caucasian people 
were confirmed in other populations such as Japanese71 or Chinese72 healthy adult male 
volunteers, both after a single oral administration and short-term multiple dosing.  
Even if bioavailability of metformin is slightly reduced by food55, it is generally 
recommended to take metformin with a meal in order to improve gastrointestinal tolerance. 
Therefore, in the context of a linagliptin plus metformin FDC, it is of interest to analyze the 
effect of a meal on the PK parameters of linagliptin. To evaluate this food effect, 32 healthy 
subjects received in a randomized order a single dose of 5 mg linagliptin after an overnight 
fast of at least 10h or immediately after the ingestion of a high-fat high-calorie breakfast73. 
Comparable bioavailability was established based on linagliptin AUC0-72. The concurrent 
intake of food increased Tmax by approximately 2 hours and reduced Cmax by about 15% 
(GMR 84.7%; 90% CI, 75.9%-94.6%). Since adequate drug exposure for inhibition of DPP-4 
was still given for the entire 24-hour dosing interval, this result was considered to be of no 
clinical relevance. Intake of a high-fat meal reduced the rate of linagliptin absorption but had 
no influence on the extent of absorption; this finding suggests that food has no relevant 
influence on the efficacy of linagliptin and that linagliptin can be given together with 
metformin during a meal. 
 2.2.2. T2DM patients 
 The PK and PD properties of multiple oral doses of linagliptin were investigated in 47 
Caucasian patients with T2DM74. They received linagliptin 1, 2.5, 5 or 10 mg, or placebo, 
once daily for 12 days. Linagliptin exposure (AUC and Cmax) increased less than 
proportionally with dose. Accumulation t1/2 was short (8.6-23.9 hours), resulting in rapid 
attainment of steady state (2-5 days) and little accumulation (range: 1.18-2.03). The long 
terminal t1/2 (113-131 hours) led to a sustained inhibition of DPP-4 activity. Renal excretion 
was below 1% on day 1 in all dose groups.  
 In a randomized, double-blind, placebo-controlled multiple dose study, 72 Japanese 
patients with T2DM were assigned to receive oral doses of linagliptin 0.5, 2.5, or 10 mg or 
placebo once daily for 28 days75. Total systemic exposure in terms of linagliptin AUC and 
Cmax increased in a less than dose-proportional manner. The terminal t1/2  was rather long 
(223-260 hours) but did not reflect the accumulation t1/2  (10.0-38.5 hours), resulting in a 
moderate accumulation ratio of <2.9 that decreased with increasing dose. Urinary excretion 
increased with linagliptin doses but was <7% at steady state for all dose groups. Thus, 
linagliptin PK profile in these Japanese patients with T2DM was consistent with the findings 
of previous studies in healthy Japanese and white patients.  
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 2.3. Linagliptin plus metformin 
 A randomized, open-label, two-way crossover design study was conducted in 16 
healthy male subjects to investigate the potential PK or PD interactions between linagliptin 
and metformin76. Linagliptin (10 mg/day) and metformin (850 mg three times daily) were 
each administered alone and concomitantly (3-9 days to steady-state). Co-administration of 
linagliptin had no apparent effect on metformin exposure (metformin AUC τ,ss). GMR co-
administration:individual administration was 101%; 90% CI was 89, 114%. Effects on 
maximum concentration at steady-state (Cmax,ss) were small (GMR: 89%; 90% CI: 78, 100). 
Co-administration of metformin did not significantly affect Cmax,ss of linagliptin (GMR: 103%; 
90% CI: 86, 124), but slightly increased AUC τ,ss by 20% (GMR: 120%; 90% CI: 107, 134). 
Metformin alone had no effect on DPP-4 activity, and the inhibition of DPP-4 caused by 
linagliptin was not affected by concomitant administration of metformin. Thus, in this small, 
multiple dose study carried out in healthy subjects, co-administration of linagliptin with 
metformin did not have a clinically relevant effect on the PK or PD of either agent76. 
Three bioequivalence studies with a similar design (open-label, randomized, single 
dose, two-way crossover, trials, in 94-96 healthy volunteers each) were performed with three 
different linagliptin/metformin FDC tablet strengths (2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 
mg/1000 mg). The results demonstrated that linagliptin/metformin hydrochloride 2.5 mg/500 
mg, 2.5 mg/850 mg, and 2.5 mg/1000 mg FDC tablets are bioequivalent to coadministration 
of corresponding doses of linagliptin and metformin as individual tablets (Table 1)51. Finally, 
the effect of food on bioavailability of linagliptin/metformin FDC was evaluated with the 
higher strength of metformin. Administration of linagliptin 2.5 mg/metformin hydrochloride 
1000 mg fixed-dose combination with a fat meal resulted in no change in overall exposure of 
linagliptin. There was no change in metformin AUC; however, mean peak serum 
concentration of metformin was decreased by 18% when administered with food. A delayed 
time-to-peak serum concentrations by 2 hours was observed for metformin under fed 
conditions. These changes are not likely to be clinically significant51. 
 
3. Pharmacodynamic evaluation 
3.1. Potential synergistic activity 
The potential synergistic activity of the two glucose-lowering agents metformin and 
linagliptin in the treatment of T2DM is illustrated in Figure 1. 
The mechanism of action of metformin mainly involves suppression of hepatic 
glucose output and modestly reduction of insulin resistance77. The inhibition of hepatic 
glucose production is mostly through a mild and transient inhibition of the mitochondrial 
respiratory chain complex I. The resulting decrease in hepatic energy status activates AMPK 
(AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted 
mechanism for the action of metformin on hepatic gluconeogenesis78. Interestingly, almost 
10 years ago already, metformin was shown to increase GLP-1 release in obese patients 
without or with T2DM79, 80. A more recent study confirmed that three months or more of 
metformin monotherapy in obese patients with T2DM was associated with increased postprandial 
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GLP-1 levels, including its active form, over a 6-h period following a standard mixed meal, 
without changes in DPP-4 activity81. These data confirmed that metformin-induced increase in GLP-
1 levels is independent of DPP-4 inhibition after a meal82, 83. The mechanisms of action 
explaining why metformin may promote GLP-1 secretion from L cells are rather complex84. 
A recent study demonstrated that metformin protects against lipoapoptosis (possibly by blocking 
JNK2 activation), and enhances GLP-1 secretion from GLP-1-producing cells in vitro85. These direct 
effects of the drug might explain the elevated plasma GLP-1 levels seen in diabetic patients on 
chronic metformin therapy81. When taken together, the combination of a DPP-4 inhibitor and 
metformin led to greater increases in active GLP-1 than either treatment alone82, 86, which 
may represent a further argument in favor of this combination87. 
In contrast to metformin, which does not exert any direct effect on the endocrine 
pancreas, the DPP-4 inhibitor linagliptin, by increasing GLP-1 and GIP (glucose-dependent 
insulinotropic polypeptide) concentrations, targets pancreatic defects present in T2DM. Indeed, 
in a glucose-dependent manner, it stimulates insulin secretion (decreased in T2DM) and 
inhibits glucagon secretion (increased in T2DM), two hormonal effects that contribute to 
reduce liver gluconeogenesis and hepatic glucose production. Thus, the combined effects of 
metformin and linagliptin result in a better control of both fasting and postprandial 
hyperglycemia in patients with T2DM (Figure 1). 
In a study investigating linagliptin PK/PD after single rising-dose (2.5 up to 600 mg) of 
linagliptin in healthy men, all doses  inhibited plasma DPP-4 activity, and single doses of 2.5 mg and 
5 mg inhibited DPP-4 activity by 72.7% and 86.1% from baseline, respectively. The time to achieve 
maximum inhibition shifted with increasing doses from 3 hours (2.5 mg) to <0.7 hours (200 mg and 
above). Within the dose range tested, a direct PK/PD relationship was observed, with a profile 
demonstrating the potency and full 24-hour duration of action of linagliptin66. 
In patients with T2DM, inhibition of plasma DPP-4 activity correlated well with 
linagliptin plasma concentrations, resulting in DPP-4 inhibition >90% in the two highest 
dose groups (5 and 10 mg once daily for 12 days); even 24 h postdose, DPP-4 inhibition was 
>80%74. Following an oral glucose tolerance test, 24 h after the last dose, statistically 
significant reductions of glucose excursions were observed with linagliptin (2.5, 5 and 10 mg 
doses) compared with placebo74. In a study of longer duration, linagliptin effectively inhibited 
plasma DPP-4 activity in patients with T2DM, producing immediate improvements in incretin levels, 
glucagon suppression, and glycemic control that were maintained throughout the 4-week study 
period88. In  5 published and 4 unpublished randomized, clinical trials identified from multiple 
databases, linagliptin 5 mg/day for 12-24 weeks, significantly reduced HbA1c (-0.63%, p < 0.00001), 
fasting plasma glucose (FPG) (-1.01 mmol/l, p < 0.00001) and improved disposition index (DI, 
product of insulin sensitivity and acute insulin secretion) (p = 0.0001)89. However, linagliptin 
monotherapy was not more effective than metformin at reducing HbA1c or FPG. Therefore, 
linagliptin is recommended as monotherapy only if metformin is not tolerated or contra-indicated and 
its main use is generally in combination with metformin90. 
3.2. Addition of linagliptin to metformin monotherapy (Table 2) 
3.2.1. Comparison versus placebo  
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The efficacy and safety of linagliptin, added to ongoing metformin therapy, were 
assessed in patients with T2DM who had inadequate glycemic control with metformin 
alone91. Patients (n=333) were randomized to receive double-blind linagliptin (1, 5 or 10 mg 
once daily) or placebo or open-label glimepiride (1-3 mg once daily). Twelve weeks of 
treatment resulted in a mean placebo-corrected lowering in HbA1c levels of 0.40% for 1 mg 
linagliptin, 0.73% for 5 mg, and 0.67% for 10 mg, compared with -0.90% for glimepiride. 
Adjusted and placebo-corrected mean changes in FPG were -1.1 mmol/l for linagliptin 1 mg, -
1.9 mmol/l for 5 mg and -1.6 mmol/l for 10 mg. There were no hypoglycemic events for 
linagliptin or placebo, whereas three patients (5%) receiving glimepiride experienced 
hypoglycemia. Thus, the addition of linagliptin to ongoing metformin treatment in patients 
with T2DM was well tolerated and resulted in significant and clinically relevant 
improvements in glycemic control, with 5 mg linagliptin being the most effective dose91. 
A 24-week, randomized, placebo-controlled, double-blind, parallel-group study 
evaluated the efficacy and safety of linagliptin administered as add-on therapy to metformin 
(≥1500 mg/day) in patients with T2DM with inadequate glycemic control (mean baseline 
HbA1c of 8.1 % and mean FPG of 9.4 mmol/l)92. The addition of linagliptin 5 mg once daily 
(n = 524) showed significant reductions vs. placebo (n = 177) in adjusted mean changes from 
baseline of HbA1c (-0.49 vs. 0.15%), FPG (-0.59 vs. 0.58 mmol/l) and 2h postprandial 
glucose (-2.7 vs. 1.0 mmol/l). Rescue glycemic therapy was less used in patients treated with 
linagliptin 5 mg than in those receiving placebo (7.8% vs.18.9%). Such improvement in 
glycemic control with linagliptin occurred without weight gain or increased risk of 
hypoglycemia.  
As metformin is administered twice daily, a fixed-dose combination of these 
compounds would require twice-daily administration of linagliptin. Therefore, a study 
evaluated whether 2.5 mg twice-daily dosing of linagliptin has comparable efficacy and safety 
to 5 mg once-daily dosing when given in addition to metformin twice daily in patients with 
inadequate glycemic control93. A total of 491 T2DM patients with HbA1c 7.0-10.0% were 
randomized to double-blind treatment with linagliptin 2.5 mg twice daily, 5 mg once daily or 
placebo, respectively, in addition to continuing metformin twice daily (≥1500 mg/day or 
maximally tolerated dose). After 12 weeks, linagliptin 2.5 mg twice daily and 5 mg once daily 
both significantly reduced HbA1c [placebo-adjusted changes from baseline (7.97%)  -0.74% 
(95% CI -0.97, -0.52) and -0.80% (95% CI -1.02, -0.58), respectively, both p < 0.0001]. The 
treatment difference (twice daily - once daily) between the linagliptin regimens was 0.06 
(95% CI -0.07, 0.19), the upper bound of which was less than the predefined noninferiority 
margin (0.35%). Hypoglycemia was rare (3.1% with linagliptin 2.5 mg twice daily, 0.9% with 
5 mg once daily, 2.3% with placebo) with no severe episodes. Linagliptin 2.5 mg twice daily 
had non-inferior HbA1c-lowering effects after 12 weeks compared to 5 mg once daily, with 
comparable safety and tolerability, in T2DM patients inadequately controlled with metformin. 
3.2.2. Comparison versus a sulfonylurea 
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Sulfonylureas are still considered as the primary add-on-therapy in several guidelines 
because of a lower cost compared to newer glucose-lowering agents3. In T2DM patients not 
well controlled by metformin monotherapy, the addition of a DPP-4 inhibitor such as 
linagliptin can be considered as a valuable alternative to the addition of a sulfonylurea, 
especially in those for whom the risk of hypoglycemia and weight gain is of concern3. In a 
recent network meta-analysis, HbA1c decrease was slightly greater for sulfonylureas 
compared with DPP-4 inhibitors [-0.12% (-0.23 to -0.03%)]18. However, most of the trials 
included in that meta-analysis were rather short term, which may favor sulfonylurea-induced 
glucose-lowering effect as early potency with secondary failure is a common finding with 
such therapy, even in patients receiving a basal therapy with metformin24, 94. Besides a lower 
weight gain compared to sulfonylureas, the advantage of a gliptin is especially of interest in 
patients at risk of hypoglycemia3. A better B-cell protection is also expected with incretin-
based therapies, which might result in a better durability of the glucose-lowering effect, 
although this remains to be proven in patients with T2DM.  
In a 2-year (the longest head-to-head study available yet), parallel-group, non-
inferiority double-blind trial, outpatients with T2DM and HbA1c 6.5-10.0% on stable 
metformin alone or with one additional oral antidiabetic drug (washed out during screening) 
were randomly assigned to linagliptin (5 mg; n=777) or glimepiride (1-4 mg; n=775) orally 
once daily in addition to metformin (daily dose ≥ 1500 mg in 93% of patients)95. Reductions 
in adjusted mean HbA1c from baseline (7.69% in both groups) to week 104 were similar in 
the linagliptin (-0.16%) and glimepiride groups (-0.36%; difference 0.20%, 97.5% CI 0.09-
0.30), meeting the predefined non-inferiority criterion of 0.35%. Fewer participants had 
hypoglycemia (7% vs. 36%, p<0.0001) or severe hypoglycemia (1 vs. 12 patients) with 
linagliptin compared with glimepiride.  
3.3. Initial linagliptin-metformin combined therapy 
 Recent recommendations emphasized the potential benefit of early combined therapy 
in the management of T2DM6. This may be explained by the complex pathophysiology of the 
disease and the numerous organ defects that are involved in T2DM and may potentially be 
targeted by pharmacological interventions2. 
A large (n=791) 24-week, double-blind, placebo-controlled, Phase III trial evaluated 
the efficacy and safety of initial combination therapy with linagliptin plus metformin versus 
linagliptin or metformin monotherapy in patients with T2DM96. Two free combination 
therapy arms received linagliptin 2.5 mg twice daily (bid) + either low (500 mg) or high 
(1000 mg) dose metformin bid. Four monotherapy arms received linagliptin 5 mg once daily, 
metformin 500 mg or 1000 mg bid or placebo. Patients with HbA1c ≥11.0% were not eligible 
for randomization and received open-label linagliptin + high-dose metformin.The placebo-
corrected mean (95% CI) change in HbA1c from baseline (8.7%) to week 24 was -1.7% (-2.0, 
-1.4) for linagliptin + high-dose metformin, -1.3% (-1.6, -1.1) for linagliptin + low-dose 
metformin, -1.2% (-1.5, -0.9) for high-dose metformin, -0.8% (-1.0, -0.5) for low-dose 
metformin and -0.6 (-0.9, -0.3) for linagliptin (all p < 0.0001). In the open-label arm, the 
mean change in HbA1c from baseline (11.8%) was -3.7%. Hypoglycemia occurred at a 
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similar low rate with linagliptin + metformin (1.7%) as with metformin alone (2.4%). Adverse 
event rates were comparable across treatment arms. No clinically significant changes in body 
weight were noted. Initial combination therapy with linagliptin plus metformin was superior 
to metformin monotherapy in improving glycemic control, with a similar safety and 
tolerability profile, no weight gain and a low risk of hypoglycemia. 
3.4. Limitations regarding the efficacy of the linagliptin-metformin combination 
It is noteworthy that T2DM patients included in the clinical trials having investigated 
the linagliptin-metformin combination, either when linagliptin was added to metformin or 
when the two drugs were used as initial combined therapy, had HbA1c levels below 11%. 
Therefore, this combination should not be recommended in patients with very poorly 
controlled T2DM, even if impressive results were reported in an open-label arm96. 
Furthermore, the overall HbA1c reduction with linagliptin 5 mg added to metformin averaged 
0.7-0.8 % at best. However, the reduction was greater in drug-naïve patients for whom a 
combined linagliptin-metformin was initiated, ranging from 1.3 to 1.7 % (placebo-subtracted 
changes). Thus, if a HbA1c level below 7% is the target, most patients with HbA1c levels 
above 8.5-9 % will not reach this goal, which opens the door to other treatment strategies3. 
4. Safety profile  
 4.1. Overall tolerance 
The safety profile of linagliptin has been analyzed in detail in previous reviews65, 97  
and is generally good and quite similar to that previously reported with other DPP-4 
inhibitors8, 98, 99. The combination of linagliptin and metformin is generally well tolerated. The 
safety/tolerance profile of linagliptin-metformin coadministration is similar to that of 
metformin alone. The safety of concomitantly administered linagliptin (daily dose 5 mg) and 
metformin (mean daily dose of approximately 1800 mg) has been evaluated in 2816 patients 
with T2DM treated for ≥12 weeks in clinical trials. Three placebo-controlled studies with 
linagliptin + metformin were conducted: 2 studies were 24 weeks in duration, 1 study was 12 
weeks in duration. In the 3 placebo-controlled clinical studies, adverse events which occurred 
in ≥5% of patients receiving linagliptin + metformin (n=875) and were more common than in 
patients given placebo + metformin (n=539) included nasopharyngitis (5.7% vs 4.3%)51. 
Cases of pancreatitis were exceptional. In a 24-week factorial design study, adverse events 
reported in ≥5% of patients receiving linagliptin + metformin were more common than in 
patients given placebo (nasopharyngitis : 6.3 vs. 1.4%; diarrhea : 6.3 vs. 2.8%) and only 
slightly higher than with either monotherapy96. Of note, the addition of linagliptin to 
metformin therapy does not appear to cause a greater incidence of gastrointestinal side effects 
than does metformin alone. 
  4.2. Body weight 
Overall, no clinically relevant changes in body weight were observed with linagliptin 
added to metformin. In a pooled analysis of 24-week phase III trials followed by a 78-week 
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open-label extension, treatment with linagliptin was not associated with a clinically relevant 
change in body weight (-0.03 kg change in subjects previously treated with linagliptin during 
the initial 24-week period, 0.47 kg in those switched from placebo)100. In a recent two-year 
head-to-head comparative trial in T2DM patients treated with metformin, body weight 
decreased with linagliptin (−1.4 kg) but increased with glimepiride (+1.3 kg) from similar 
mean baseline values (86.0  vs 87.0  kg); the treatment difference was −2.7 kg (97.5% CI −3.2 
to −2.2, p<0.0001). 
 
4.3. Hypoglycemia 
The likelihood of treatment-related hypoglycemia is very low with the dual 
combination metformin plus linagliptin, but increased when linagliptin or linaglipin-
metformin are coprescribed with a sulfonulyrea100. In a large (n=1058 T2DM patients) multi-
centre, 24-week, randomized, double-blind, parallel-group study comparing linagliptin (5 mg 
once daily) and placebo when added to metformin plus sulfonylurea, symptomatic 
hypoglycemia occurred in 16.7 and 10.3% of the linagliptin and placebo groups, 
respectively48. Hypoglycemia was generally mild or moderate and no more severe 
hypoglycemia was reported with linagliptin than with placebo. 
 
4.4. Cardiovascular events 
Of potential interest, preliminary data from a 104-week trial showed a lower incidence 
of cardiovascular events with linagliptin added to metformin compared with the addition of a 
sulfonylurea (glimepiride) to metformin (12 vs. 26 patients; relative risk 0.46, 95% CI 0.23-
0.91, p=0.0213)95. This observation is in agreement with the potential beneficial effect of 
DPP-4 inhibitors on cardiovascular outcomes.101 Further information on the cardiovascular 
safety and efficacy of linagliptin versus glimepiride will be provided by the ongoing 
prospective CAROLINA (“CARdiovascular Outcome study of LINAagliptin versus 
glimepiride in patients with T2DM”) study in which numerous patients will receive 
metformin as baseline therapy102. Meta-analyses reported that both metformin103 and 
linagliptin104 may be associated with a reduced incidence of cardiovascular events, suggesting 
that combination of the two drugs may be of potential interest in T2DM patients at high 
cardiovascular risk. 
 
4.5. Safety in patients with CKD 
One particularity of linagliptin is that this DPP-4 inhibitor may be safely and 
effectively used in all T2DM patients whatever the renal function (even in patients with 
severe CKD)105. In contrast, the use of metformin in patients with mild to moderate CKD is 
either contraindicated (as stated in the labeling) or at least limited, with dose reduction and 
regular careful supervision of renal function as proposed more recently3, 46. The safety aspects 
of using linagliptin and metformin in patients with mild to moderate CKD will be more 
extensively discussed in a further paper106. 
 
5. Linagliptin plus metformin FDC  
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Linagliptin plus metformin combination, given separately, has proven its superiority as 
compared to either monotherapy96. However, there is no study published as full peer-reviewed 
paper having evaluated the long-term effect of the FDC linagliptin plus metformin. The FDC 
(Jentadueto®) has been developed as tablets with three different dosage forms and strengths 
to be administered twice daily : linagliptin 2.5 mg plus metformin hydrochloride 500 mg, 
linagliptin 2.5 mg plus metformin hydrochloride 850 mg and linagliptin 2.5 mg plus 
metformin hydrochloride 1000 mg. This FDC may be prescribed when treatment with both 
linagliptin and metformin are appropriate. In the treatment of patients with T2DM, the FDC 
linagliptin plus metformin FDC (Jentadueto®)  is indicated : 1) as an adjunct to diet and 
exercise to improve glycemic control in adult patients inadequately controlled on their 
maximal tolerated dose of metformin alone93; 2)  in those already being treated with the 
combination of linagliptin and metformin96; and  3) in combination with a sulfonylurea (i.e. 
triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately 
controlled on their maximal tolerated dose of metformin and a sulfonylurea48, 49. The 
recommended starting doses are as follows : in patients currently not treated with metformin, 
initiate treatment with 2.5 mg linagliptin/500 mg metformin hydrochloride twice daily;  in 
patients already treated with metformin, start with 2.5 mg linagliptin and the current dose of 
metformin taken at each of the two daily meals (e.g., a patient on metformin 1000 mg twice 
daily would be started on 2.5 mg linagliptin/1000 mg metformin hydrochloride twice daily 
with meals);  in patients already treated with linagliptin and metformin individual components 
may be switched to Jentadueto® FDC containing the same doses of each component. The 
dosage should be individualized on the basis of both effectiveness and tolerability, while not 
exceeding the maximum recommended dose of 2.5 mg linagliptin/1000 mg metformin 
hydrochloride twice daily. Dose escalation should be gradual to reduce the gastrointestinal 
side effects associated with metformin use. Because of the presence of metformin, 
Jentadueto®  is not recommended in hepatic impairment or hypoxic states and is 
contraindicated in renal impairment, although such restriction might be dampened in a near 
future provided that patient’s careful supervision is warranted106. 
6. Conclusion 
 The combination of metformin, the first choice glucose-lowering drug, and a DPP-4 
inhibitor such as linagliptin sounds as a valuable option in the management of patients with 
T2DM. Indeed the two compounds act via different, albeit complementary, mechanisms 
leading to an at least additive glucose-lowering activity, with overall a good safety profile. On 
the one hand, metformin acts predominantly by inhibiting hepatic glucose production but is 
also associated with a slight increased production of GLP-1 by intestinal L cells. On the other 
hand, linagliptin increases endogenous GLP-1 levels by inhibiting the metabolism of this 
incretin gut hormone, an effect that is associated with an increase in insulin secretion and a 
suppression of glucagon secretion in a glucose-appropriate fashion. Thus, combining both 
agents results in a further increase of GLP-1 levels. In addition, the modes of action of the two 
compounds tackle various main defects in the pathophysiology of T2DM, i.e. impaired insulin 
secretion, increased glucagon levels, increased hepatic glucose production and decreased 
insulin sensitivity. Despite the fact that both pharmacological agents are substrates of OCT1 
and OCT2, there is no clinically relevant PK DDIs between linagliptin and metformin 
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reported so far. Linagliptin may be used in T2DM patients with any degree of renal 
impairment, because its almost absence of renal excretion, a characteristic that differentate the 
drug from other DPP-4 inhibitors. In contrast, caution is recommended with metformin use in 
patients with mild to moderate CKD because of the risk of drug accumulation and lactic 
acidosis, a rare but potentaily fatal complication. Thus, linagliptin plus metformin, either 
separately or as FDC, can only be prescribed when treatment with both pharmacological 
agents is appropriate. Statistically significant and clinically relevant reductions in plasma 
glucose and HbA1c levels have been described in patients not reaching individually selected 
HbA1c targets despite diet and exercise, metformin alone or even metformin plus 
sulfonylurea therapies. No adverse effects have been reported, especially no weight gain and 
no severe hypoglycemia. Further studies are waited to demonstrate the long-term benefit of 
the linagliptin plus metformin combination, especially regarding a reduction of diabetes 
vascular complications.  
EXPERT OPINION SECTION 
 Type 2 diabetes (T2DM) is a complex and quite heterogeneous disease. The 2012 joint 
position statement from the American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) recommends a patient-centred approach in the 
management of hyperglycemia in patients with T2DM. It is generally agreed that metformin, 
if not contraindicated and if tolerated, is the preferred and most cost-effective first 
pharmacological agent. It is initiated at, or soon after, diagnosis, especially in patients in 
whom lifestyle intervention alone has not achieved, or is unlikely to achieve, individualized 
glycated hemoglobin (HbA1c) goals. If monotherapy alone does not achieve/maintain an 
HbA1c target over ~3 months, the next step would be to add a second glucose-lowering agent. 
On average, any second agent is typically associated with an approximate further reduction in 
HbA1c of ~1%. With a distinct paucity of long-term comparative effectiveness trials 
available, uniform recommendations on the best agent to be combined with metformin cannot 
be made, as stated in the ADA-EASD document. Thus, advantages and disadvantages of 
specific drugs for each patient should be considered. Choice is based on patient and drug 
characteristics, with the overriding goal of improving glycemic control while minimizing side 
effects. In this regard, the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor may offer 
potential benefits over classical sulfonylureas in T2DM patients at risk of hypoglycemia and 
in those overweight who fear further weight gain.  
The clinical studies presented so far with the novel DPP-4 inhibitor linagliptin as add-
on therapy to metformin showed clinically relevant improvement in glycemic control. Mean 
HbA1c levels were reduced by approximately 0.65%–0.80% from a baseline of 7.9%–8.5% 
with linagliptin 5 mg compared to placebo. Furthermore, the combination was tolerable and 
safe with similar adverse events profile as placebo-treated patients given metformin alone. As 
with other DPP-4 inhibitors, the addition of linagliptin to metformin monotherapy was weight 
neutral and was not associated with any increased risk of hypoglycemia.  
Linagliptin has a unique pharmacokinetic profile compared to other DPP-4 inhibitors, 
with a very low renal excretion and a predominant biliary excretion. This characteristic allows 
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use linagliptin in T2DM patients with chronic kidney disease (CKD : from mild to severe) 
without contra-indication and any dose adjustment. Considering the large number of patients 
with some degree of renal impairment (especially in the elderly population), this may 
represent an advantage over other DPP-4 inhibitors. Indeed, for the latter, a dose adjustment is 
required according to the reduction of estimated glomerular filtration rate (eGFR) that should 
be regularly and carefully monitored. However, the linagliptin plus metformin combination, 
especially the novel fixed-dose combination (FDC : Jentadueto®), can not be used in T2DM 
patients with renal impairment according to official guidelines because of the presence of 
metformin and the potential risk of lactic acidosis in case of biguanide accumulation. 
The use of metformin in patients with renal impairment remains, however, 
controversial. According to the official label, metformin should not be used above a certain 
threshold of serum creatinine or when eGFR is below 60 ml/min/m². However, in clinical 
practice, numerous T2DM patients are currently treated with metformin despite an eGFR 
below this limit, without any adverse events and even, with potential benefits. There is an 
ongoing debate as to whether these thresholds are too restrictive and thereby not allow 
patients with mild-moderate renal impairment gain more benefit than harm from using 
metformin. In the UK, the National Institute for Health and Clinical Excellence (NICE) 
guidelines are less proscriptive, generally allowing use of metformin down to a GFR of 30 
ml/min, with dose reduction advised at 45 ml/min. If so, the use of linagliptin plus metformin, 
either separately or as FDC, would be extended to a larger population of patients with T2DM 
and the specific advantage of linagliptin regarding its use independent of renal function would 
even be better appreciated in clinical practice. 
 In general, a FDC may offer some advantages in clinical practice. By increasing 
convenience, it could increase patient’s adherence. Adherence to therapy is, indeed, a major 
concern in patients with T2DM who generally share several chronic comorbidities and 
thereby should receive multiple medications. However, as the classical formulation of 
metformin hydrochloride should be given twice daily, the linagliptin plus metformin FDC has 
also to be given twice daily while once daily administration of linagliptin is enough to 
maintain sustained DPP-4 inhibition over 24 hours. Furthermore, a FDC combination has the 
disadvantage not to allow an easy titration of each of the two individual agents. Because 
metformin should be titrated to improve gastrointestinal tolerance, various FDC forms with 
different strengths of metformin have been developed. However, the FDC with the lower 
dosage of metformin – 500 mg – will not be launched in Europe and this decision would not 
allow use the FDC in patients with mild renal impairment for whom metformin dosage should 
be reduced according to the eGFR level. 
In the ADA-EASD position statement, initial combination drug therapy is limited to 
patients with a high baseline HbA1c (e.g. ≥9.0% [≥75 mmol/mol]) who have a low 
probability of achieving a near-normal target with monotherapy. It may therefore be justified 
to start directly with a combination of two glucose-lowering agents in this circumstance. 
During recent years, however, there has been a discussion of introducing initial combination 
therapy (instead of metformin alone) when pharmacological treatment is required for T2DM, 
in order to reach therapeutic goal at an earlier stage, have a better stabilisation of this evolving 
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disease and avoid or delay subsequent changes in therapy for the maintenance of therapeutic 
goal. Because the complementary effects of linagliptin and metformin lead to robust and 
sustained improvements in glycemic control, initial combination of the two agents may be 
considered as a useful treatment option for patients withT2DM. However, the durability of the 
glucose-lowering effect of the combination linagliptin plus metformin needs to be further 
explored in long-term controlled trials. Especially, its superiority regarding clinical 
(cardiovascular) outcomes, compared to the classical metformin-sulfonylurea combination, 
remains to be demonstrated in further large prospective trials, such as CAROLINA. 
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Figure 1 : Synergistic effects of metformin and linagliptin on blood glucose control in patients 
with T2DM. AMPK : AMP-activated protein kinase. DPP-4 : dipeptidyl peptidase-4. GLP-1 : 




Table 1 : Results from open-label, randomized, single dose, two-way crossover, trials studying the bioequivalence between fixed-dose combinations (FDC) and 
separate tablets of linagliptin (2.5 mg) and three different strengths of metformin hydrochloride (1000 mg  500 mg and 850 mg) in 94-96 healthy volunteers 
(arithmic means and SD). Adapted from reference.51 
 
Treatment 
LINA/MET 2.5 mg/1000 mg FDC 
vs.  
LINA 2.5 mg + MET 1000 mg 
LINA/MET 2.5 mg/500 mg FDC 
vs.  
LINA 2.5 mg + MET 500 mg 
LINA/MET 2.5 mg/850 mg FDC 
vs.  














LINAGLIPTIN PLASMA LEVELS 
FDC (test) 163 ± 45.9 5.20 ± 1.25 188 ± 50.6 5.53 ± 1.51 165 ± 42.6 5.38 ± 1.31 
LINA+MET 
(reference) 
192 ± 39.0 5.03 ± 1.20 188 ± 50.5 5.64 ± 1.56 160 ± 42.9 5.10 ± 1.19 


























METFORMIN PLASMA LEVELS 
FDC (test) 11300 ± 2930 1740 ± 462 7530 ± 1840 1170 ± 315 11400 ± 2840 1710 ± 458 
LINA+MET 
(reference) 
10800 ± 2830 1670 ± 478 7590 ± 1910 1200 ± 329 11400 ± 3030 1730 ± 501 














LINA = linagliptin. MET = metformin. FDC : fixed-dose combination. AUC0-72 : area under the plasma concentration-time curve from time zero to 72 hours. 
AUC0-Z : area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentration above the quantification limit. Cmax : 
maximum plasma concentration. 
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Table 2 : Main randomized controlled trials assessing the efficacy of the combination linagliptin-metformin in patients with T2DM treated with metformin 





























Linagliptin added to metformin monotherapy 
Comparison versus Placebo 
Forst et al 201091 
Linagliptin  5 mg od 66 12 8.50 69.4 -0.48 -1.22 -0.57 
Linagliptin 10 mg od 66 12 8.40 68.3 -0.42 -0.90 -1.27 
Placebo od 71 12 8.40 68.3 +0.25 +0.70 -0.84 
Taskinen et al 201192 
Linagliptin 5 mg od 523 24 8.09 64.9 -0.49 -0.60 -0.50 
Placebo od 177 24 8.02 64.2 +0.15 +0.60 -0.40 
Ross et al 201293 
Linagliptin  5 mg od 224 12 7.98 63.7 -0.52 -0.99* -1.0 
Linagliptin 2.5 mg bid 223 12 7.96 63.5 -0.46 -0.76* -0.4 
Placebo 44 12 7.92 63.1 +0.28 - -1.1 
Comparison versus Glimepiride 
Forst et al 201091 
Linagliptin 5 mg od 66 12 8.50 69.4 -0.48 -1.22 -0.57 
Glimepiride 1-3 mg od 65 12 8.20 66.1 -0.68 NA +0.73 
Gallwitz et al 201295 
Linagliptin 5 mg od 776 104 7.70 60.7 -0.16 -0.13 -1.4 
Glimepiride 1-4 mg od 775 104 7.70 60.7 -0.36 -0.48 +1.3 
Initial linagliptin-metformin therapy in diet-treated patients 
Haak et al 201296 
Linagliptin 5mg od 135 24 8.70 71.6 -0.50 -0.50 +0.2 
Metformin 500mg bid 141 24 8.70 71.6 -0.60 -0.90 -0.7 
Metformin 1000 mg bid 138 24 8.50 69.4 -1.10 -1.80 -0.5 
Linagliptin 2.5 mg +     
Metformin 500 bid 
137 24 8.70 
71.6 -0.20 -1.80 -0.1 
Linagliptin 2.5 mg +  140 24 8.70 71.6 -1.60 -2.70 -0.8 
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Metformin 1000 mg bid 
Placebo 65 24 8.70 71.6 +0.1 +0.60 -0.7 
 
Reduction = changes at end of follow up versus baseline (not versus comparator). FPG : fasting plasma glucose. NA : not available. Od : once daily. Bid : 
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 Linagliptin increases glucagon-like peptide-1 (GLP-1) levels by inhibiting dipeptidyl peptidase-4 
(DPP-4) and thereby enhances insulin secretion and reducing glucagon levels while metformin acts 
primarily by inhibiting hepatic glucose production but also promotes the secretion of GLP-1. These 
complementary metabolic actions result in an additive glucose-lowering activity for the management 
of type 2 diabetes.   
 Metformin is mainly excreted by the kidneys whereas linagliptin has a negligible renal excretion (in 
contrast to other DPP-4 inhibitors) but has a predominant biliary excretion. Therefore, metformin is 
contraindicated in presence of renal impairment (or the dosage should be reduced according to the 
glomerular filtration rate) whereas linagliptin may be used at the same dosage of 5 mg/day whatever 
the level of kidney function (even in case of severe renal impairment).  
 There are no pharmacokinetic drug-drug interactions between linagliptin and metformin and a fixed-
dose combination (FDC) has proven to be bioequivalent compared to separate tablets. Linagliptin 
and metformin can be given with food either separately or as a FDC. No titration is required for 
linagliptin (5 mg once daily when given separately or 2.5 mg twice daily as FDC) but a initial 
titration of metformin is generally recommended to improve gastrointestinal tolerance (which 
explains the different strengths of metformin in the proposed FDCs  
 When linagliptin is added to metformin, a clinically relevant reduction of glycated hemoglobin (HbA1c) 
of almost 0.8 % could be obtained, without weight gain and without hypoglycemia. The improvement of 
glucose control was non inferior to that observed with the sulfonylurea glimepiride, with a better 
tolerance profile. Initial combination in drug-naïve patients has also proven to be remarkably effective 
and more potent than either individual component.  
 The use of the linagliptin plus metformin in patients with mild to moderate chronic kidney disease 
remains a matter of debate. Preliminary analysis suggest that linagliptin (combined with metformin) 
may reduced the incidence of cardiovascular events in patients with type 2 diabetes and such a 
protective cardiovascular effect is currently tested in the ongoing prospective trial CAROLINA 
comparing linagliptin with glimepiride.  
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